Precigen (NASDAQ:PGEN) Given “Buy” Rating at B. Riley Financial

Precigen (NASDAQ:PGEN – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at B. Riley Financial in a research note issued on Monday, Benzinga reports. They presently have a $11.00 target price on the biotechnology company’s stock, down from their prior target price of $12.00. B. Riley Financial‘s price objective suggests a potential upside of 142.29% from the company’s previous close.

Several other brokerages have also issued reports on PGEN. Zacks Research lowered Precigen from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Raymond James Financial set a $12.00 target price on Precigen in a research note on Thursday, November 5th. HC Wainwright upped their target price on Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Citigroup reaffirmed a “market outperform” rating on shares of Precigen in a research note on Thursday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research note on Thursday, October 15th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $13.25.

Read Our Latest Stock Report on Precigen

Precigen Price Performance

PGEN stock opened at $4.54 on Monday. The company has a 50 day moving average of $6.74 and a two-hundred day moving average of $5.28. The company has a market cap of $1.63 billion, a price-to-earnings ratio of 45.40 and a beta of 1.01. Precigen has a 12-month low of $3.04 and a 12-month high of $8.98. The company has a quick ratio of 4.83, a current ratio of 5.58 and a debt-to-equity ratio of 1.12.

Precigen (NASDAQ:PGEN – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. Precigen had a net margin of 15.55% and a return on equity of 57.93%. The business had revenue of $74.15 million for the quarter, compared to analysts’ expectations of $71.55 million. During the same period in the previous year, the company posted ($1.06) EPS. Precigen’s revenue was up 2437.6% on a year-over-year basis. On average, equities analysts anticipate that Precigen will post 0.23 earnings per share for the current fiscal year.

Insider Activity at Precigen

In other news, Director Jeffrey B. Kindler sold 185,000 shares of the firm’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the transaction, the director owned 17,100 shares in the company, valued at approximately $127,224. This trade represents a 91.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Rutul R. Shah sold 15,342 shares of Precigen stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $7.50, for a total transaction of $115,065.00. Following the completion of the sale, the chief operating officer directly owned 468,865 shares of the company’s stock, valued at approximately $3,516,487.50. The trade was a 3.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 235,000 shares of company stock valued at $1,751,400 over the last three months. Insiders own 41.40% of the company’s stock.

Hedge Funds Weigh In On Precigen

Several hedge funds have recently bought and sold shares of the business. Commonwealth Equity Services LLC increased its stake in shares of Precigen by 5.9% in the third quarter. Commonwealth Equity Services LLC now owns 52,532 shares of the biotechnology company’s stock worth $450,000 after purchasing an additional 2,909 shares during the period. Cetera Investment Advisers lifted its position in shares of Precigen by 0.9% during the 1st quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock worth $1,449,000 after purchasing an additional 3,250 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in shares of Precigen by 10.6% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 44,000 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 4,200 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Precigen by 10.5% during the 2nd quarter. Arizona State Retirement System now owns 53,713 shares of the biotechnology company’s stock worth $306,000 after purchasing an additional 5,086 shares during the last quarter. Finally, Carolina Wealth Advisors LLC bought a new stake in Precigen during the 3rd quarter valued at approximately $46,000. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Company Profile

(Get Free Report)

Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies, including engineered immunotherapies. The company is based in Germantown, Maryland, and its roots include Intrexon, which adopted the Precigen name in 2020. Its approved product, PAPZIMEOS (zopapogene imadenovec-drba), is a gene therapy for adults with recurrent respiratory papillomatosis, a rare condition associated with human papillomavirus types 6 and 11. Precigen is also developing investigational therapies for cancers and other diseases.

Further Reading

Analyst Recommendations for Precigen (NASDAQ:PGEN)

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.